Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
6
Next ›
Last »
FNIH Ultra-Rare Cancer Drug Development Partnership Likely To Move Forward; FDA Agrees Time Is Right For New Model That Won’t Compete With Commercial R&D
August 25, 2023
Prevision Policy Clips | Kidney Transplant Drugs: FDA Workshop Will Focus On Pathways To Encourage More Tolerable Therapies
August 25, 2023
Prevision Policy Clips | Oncopeptides Pepaxto Withdrawal Formally Proposed By FDA: First Test Of New FDORA Pathway
August 24, 2023
FDA And “Three Spheres” Of Artificial Intelligence: Califf Sees Internal Benefits For Freeing Up Personnel, Predictive Modeling Requires Continuous Updates
August 23, 2023
Prevision Policy Clips | Intarcia Fight To Salvage Exenatide Combo Product NDA Will Go To Advisory Committee
August 23, 2023
Part D Co-Pay “Smoothing”: CMS Objects To Debit Card Model In Draft Guidance Implementing IRA Provision; Two-Part Guidance Is Reminder That There Are No Simple Changes In Part D
August 22, 2023
Prevision Policy Clips | Part D “Smooth” Co-Pay Guidance Will Be Issued In Two Parts, CMS Says
August 22, 2023
FDA Informed Consent Guidance Sticks To Themes Of Establishing Safeguards In Complex Research Populations But Gives IRBs Flexibility When “New Information” Arises
August 21, 2023
Prevision Policy Clips | Amgen Lumakras AA Conversion Application Will Provide ODAC Case Study For “Successful” PFS Trial With Adverse Survival
August 21, 2023
Biosimilar Supplement Applications: FDA Offers Details On New Review Categories Under BsUFA III
August 18, 2023
Prevision Policy Clips | Hydroxychloroquine, Ephedrine Fail To Make FDA 503B Bulk Drug List For Compounding By Outsourcing Facilities
August 18, 2023
Prevision Policy Clips | Labeling For Biosimilar And Interchangeable Products Draft Guidance Under Review At OMB
August 17, 2023
Prevision Policy Clips | AZ Warning Letter For Breztri Aerosphere Is First Issued By FDA Office of Prescription Drug Promotion In 2023
August 16, 2023
Prevision Policy Clips | US WorldMeds Eflornithine Neuroblastoma Relapse Prevention NDA Will Be Reviewed By ODAC On October 4
August 15, 2023
Prevision Policy Clips | CDER Net Hiring Far Outpacing CBER With 186 New Hires Compared To Only Three Net Gains
August 14, 2023
Postmarket Data Collection Guidance For Underrepresented Groups Provides Broad FDA Advice On Approaches; Real-World Data Among Options
August 11, 2023
Prevision Policy Clips | Value-Based Purchasing Agreements In ALS: “There’s No Leverage”
August 11, 2023
Prevision Policy Clips | Postmarket Data Collection Guidance On Underrepresented Populations Features “Mechanisms” By Which FDA Can Request Or Require Information
August 10, 2023
Sickle Cell Gene Therapies Continue ICER Positive Gene Therapy Reviews; Past Inequities Create Favorable Context For Price/Coverage
August 9, 2023
Prevision Policy Clips | Postapproval Pregnancy Safety Studies: FDA/Duke Margolis Workshop Sept. 18-19
August 9, 2023
QTc Labeling Draft Guidance For Non-Antiarrhythmic Drugs: “Reasonable Evidence” Of Causal Cardiac Events Should Result In Boxed Warning, FDA Says
August 8, 2023
Prevision Policy Clips | FDA Schedules Listening Session On Product Recalls For Sept 29
August 8, 2023
Prevision Policy Clips | Sage/Biogen Zurzuvae Split Decision By FDA Approves Post-Partum Depression
August 7, 2023
Prevision Policy Clips | AZ/Sanofi Beyfortus Enthusiastically Endorsed By ACIP, Despite Concern About Price
August 4, 2023
Office Of Therapeutic Products Director Verdun Is A CBER Veteran; Internal Candidate Chosen For High-Profile Post Overseeing Gene/Cell Therapy Reviews
August 3, 2023
1
2
3
4
5
6
Next ›
Last »